Iantrek
PrivateLast Round
Debt
Apr 28, 2026
Est. Valuation
$95M
Total Funding Raised
$100.22M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Iantrek operates in Healthcare & Life Sciences and is based in White Plains, New York. Its latest recorded funding round was a Debt round in April 2026.
Iantrek is an ophthalmic medical technology company that develops micro- and bio-interventional solutions for the surgical treatment of chronic eye diseases, with a primary focus on glaucoma.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology
Business Model
B2B
Customer Profile
Hardware Sales, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Iantrek Comparables
Compare Iantrek with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Avisi Technologies Inc. | 85% | |
| Myra Vision | 84% | |
| Sight Sciences | 83% |
For institutional investors. Book with your work email.
Iantrek Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Debt | Apr 28, 2026 | ||||
| Series C | Aug 20, 2025 | ||||
| Series B | Aug 30, 2022 | ||||
| Series A Extension | Oct 22, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Iantrek Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| U.S. Venture Partners | Series C |
| aMoon | Series C |
| Trinity Capital | Debt |
| Sectoral | Series C, Series B |
| Visionary Ventures | Series C, Series B |
| Civilization Ventures | Series C |
| JSD Capital | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 28, 2026
$30M round led by Trinity Capital.
- Mar 31, 2026
Introducing AlloSpan Canal, a bio-reinforced platform for ophthalmic surgery.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 8, 2026
Iantrek, Inc. plans to present two CREST study analyses at the 2026 American Academy of Ophthalmology, taking place Oct 9th-12th '26 in Louisiana.
For institutional investors. Book with your work email.
Iantrek Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Iantrek's valuation, stock price, and market status.
Is Iantrek a public or private company?
Iantrek is a private company.
What is the current stock price of Iantrek?
Iantrek is a private company, so its shares have no public market price. Caplight tracks Iantrek's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Iantrek worth (valuation)?
Iantrek's valuation is estimated at $95.0M based on funding round data.
Can I buy Iantrek stock?
Iantrek shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Iantrek's last funding round?
Iantrek's most recent funding round was Debt on April 28, 2026.
Who are the main investors in Iantrek?
Key investors in Iantrek include U.S. Venture Partners, Trinity Capital, Sectoral, Visionary Ventures.
Will Iantrek IPO soon?
No public IPO plans have been announced for Iantrek.
How can I track Iantrek secondary market activity?
Caplight tracks bids, offers, and trades in Iantrek's shares on secondary markets.